- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03537573
Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care
Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Non-Cancer Pain in Primary Care
The investigators will assess whether behavioral science-based interventions can "nudge" providers towards more evidence-based care for patients with acute non-cancer pain.
Aim 1) Among opioid naïve primary care patients with acute non-cancer pain, compare the effect of the provider-targeted behavioral interventions (opioid justification and provider comparison), individually and in combination, on initial opioid prescription, initial use of non-opioid management, and patient-reported pain and function.
Aim 2) Compare the effect of the 2 provider-targeted behavioral interventions, individually and in combination, on unsafe opioid prescribing and transition to chronic opioid therapy.
Aim 3) Assess provider satisfaction and experience with the provider-targeted behavioral interventions.
Hypotheses:
Aim 1, H1a: Compared with the guideline (usual care) alone, the addition of the opioid justification and provider comparison behavioral interventions will be associated with a decreased proportion of opioid prescription and increased proportion of non-opioid management at the initial outpatient visit for acute non-cancer pain.
Aim 1, H1b: Compared with usual care (guideline) alone, the addition of the opioid justification and provider comparison behavioral interventions will be associated with no difference in patient-reported pain, function, and satisfaction at 1, 6, and 12 months.
Aim 2, H2: Compared with the usual care (guideline), the addition of opioid justification and provider comparison behavioral interventions will be associated with a decreased proportion of patients receiving unsafe opioid therapy and a decreased proportion of patients transitioning to chronic opioid therapy.
Study Design: Pragmatic, cluster-randomized clinical trial in 48 primary care clinics.
Study Population: The patient population will be 19,855 opioid naïve adults who present to clinic with acute uncomplicated musculoskeletal pain or headache.
Primary and Secondary Outcomes: The primary outcome measures will be receipt of an initial opioid prescription and unsafe opioid prescribing. Secondary outcomes will be non-opioid pain management, and, in 514 patients, patient-reported pain and function.
Analytic Plan: The investigators will test for differences in the primary and secondary outcomes among the 4 intervention groups.
Once completed, the project will provide evidence that health systems and other stakeholders need to implement interventions to prevent unsafe opioid prescribing.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- UPMC Community Medicine Incorporated
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Patient Participants
Inclusion Criteria:
- Age 18 years or older; ii) index outpatient encounter with International Classification of Disease (ICD)-10 code for acute neck, back, or other musculoskeletal and headache diagnosis ("acute" defined as no similar diagnosis in past 3 months).
Exclusion Criteria:
- Cancer diagnosis (other than non-melanoma skin cancer)
- Receipt of opioid prescription within 12 months of index outpatient encounter
- Providers
Inclusion Criteria:
- Primary care provider (MD, Doctor of Osteopathy (DO), Physician Assistant (PA), Nurse Practitioner (NP)) at participating practice
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Usual Care/Guideline
The Usual Care group (also known as the Guideline group) follows the recent Center for Disease Control (CDC) guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy.
Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
|
The Usual Care group (also known as the Guideline group) follows the recent CDC guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy.
Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
|
Experimental: Guideline + Opioid Justification (OJ)
Providers will be required asked to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition.
The provider will be notified that the justification provided will be visible in the Epic EHR.
The provider has the option of entering a justification or not.
If no justification is entered, nothing will be entered into the record (i.e., the Opioid Justification area in the encounter record will be left blank).
The provider does not need to enter a justification if they choose to cancel the opioid prescription.
|
The Usual Care group (also known as the Guideline group) follows the recent CDC guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy.
Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
Providers will be required asked to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition.
The provider will be notified that the justification provided will be visible in the Epic EHR.
The provider has the option of entering a justification or not.
If no justification is entered, nothing will be entered into the record (i.e., the Opioid Justification area in the encounter record will be left blank).
The provider does not need to enter a justification if they choose to cancel the opioid prescription.
|
Experimental: Guideline + Provider Comparison (PC)
Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids f or acute pain who transition to chronic opioid therapy (> 3 months).
Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions , unsafe opioid prescribing, and transition to chronic opioid therapy (> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain.
Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
|
The Usual Care group (also known as the Guideline group) follows the recent CDC guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy.
Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids or acute pain who transition to chronic opioid therapy (> 3 months).
Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions, unsafe opioid prescribing, and transition to chronic opioid therapy (> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain.
Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
|
Experimental: Guideline + OJ + PC
This arm will include the guideline, opioid justification, and provider comparison described above.
|
The Usual Care group (also known as the Guideline group) follows the recent CDC guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy.
Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
Providers will be required asked to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition.
The provider will be notified that the justification provided will be visible in the Epic EHR.
The provider has the option of entering a justification or not.
If no justification is entered, nothing will be entered into the record (i.e., the Opioid Justification area in the encounter record will be left blank).
The provider does not need to enter a justification if they choose to cancel the opioid prescription.
Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids or acute pain who transition to chronic opioid therapy (> 3 months).
Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions, unsafe opioid prescribing, and transition to chronic opioid therapy (> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain.
Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Initial Opioid Prescription
Time Frame: 1 day (assessed on day of initial qualifying clinic visit
|
Initial opioid prescription (yes/no) (Primary) (Hypothesis 1a).
Opioid prescription at qualifying clinic visit, measured via electronic health record (EHR).
|
1 day (assessed on day of initial qualifying clinic visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Initial non-opioid management
Time Frame: 1 day (assessed on day of initial qualifying clinic visit)
|
Initial non-opioid management (yes/no) (Secondary) (Hypothesis 1a).
Defined as order for any non-opioid management strategy at baseline (e.g., non-opioid medication, physical therapy, behavioral therapy), measured via EHR.
|
1 day (assessed on day of initial qualifying clinic visit)
|
Change in Patient Reported Pain and Function
Time Frame: Assessed at 1, 6, and 12 months after initial qualifying clinic visit
|
Change in Patient Reported Pain and Function (Secondary) (Hypothesis 1b).
Measured by the 3-item Pain/Enjoyment/General Activities (PEG) instrument in clinic at baseline and via brief web survey or telephone interview
|
Assessed at 1, 6, and 12 months after initial qualifying clinic visit
|
Unsafe opioid prescribing at 3 months
Time Frame: 3 months after initial qualifying clinic visit
|
Defined over the prior 3 months as any of: a) receipt of initial extended release/long-acting opioid for acute pain; b) > 100 morphine milligram equivalent dose per day; c) opioid prescription in patients with substance use disorder or concurrent benzodiazepine prescription.
|
3 months after initial qualifying clinic visit
|
Unsafe opioid prescribing at 6 months
Time Frame: 6 months after initial qualifying clinic visit
|
Defined over the prior 3 months as any of: a) receipt of initial extended release/long-acting opioid for acute pain; b) > 100 morphine milligram equivalent dose per day; c) opioid prescription in patients with substance use disorder or concurrent benzodiazepine prescription.
|
6 months after initial qualifying clinic visit
|
Unsafe opioid prescribing at 12 months
Time Frame: 12 months after initial qualifying clinic visit
|
Defined over the prior 3 months as any of: a) receipt of initial extended release/long-acting opioid for acute pain; b) > 100 morphine milligram equivalent dose per day; c) opioid prescription in patients with substance use disorder or concurrent benzodiazepine prescription.
|
12 months after initial qualifying clinic visit
|
Chronic opioid therapy at 3 months
Time Frame: 3 months after initial qualifying clinic visit
|
Chronic opioid therapy (Secondary) (Hypothesis 2).
Ongoing, chronic opioid therapy will be measured via EHR
|
3 months after initial qualifying clinic visit
|
Chronic opioid therapy at 6 months
Time Frame: 6 months after initial qualifying clinic visit
|
Chronic opioid therapy (Secondary) (Hypothesis 2).
Ongoing, chronic opioid therapy will be measured via EHR
|
6 months after initial qualifying clinic visit
|
Chronic opioid therapy at 12 months
Time Frame: 12 months after initial qualifying clinic visit
|
Chronic opioid therapy (Secondary) (Hypothesis 2).
Ongoing, chronic opioid therapy will be measured via EHR
|
12 months after initial qualifying clinic visit
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kevin L Kraemer, MD, University of Pittsburgh
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UOP-1609-36881
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Musculoskeletal Pain
-
Sykehuset i Vestfold HFActive, not recruitingBack Pain | Musculoskeletal Pain | Chronic Pain | Musculoskeletal Diseases or Conditions | Pain, Chronic | Musculoskeletal Disorder | Musculoskeletal Neck PainNorway
-
University of Missouri, Kansas CityTerminatedOrthopaedic Related Pain (Musculoskeletal Pain)United States
-
Uppsala UniversityDalarna County Council, Sweden; Center for Clinical Research Dalarna, Sweden; REHSAM, SwedenTerminatedMusculoskeletal Neck Pain | Musculoskeletal Shoulder PainSweden
-
NORCE Norwegian Research Centre ASHelse Sor-Ost; Sykehuset i Vestfold HFCompletedNeck Pain Musculoskeletal | Back Pain Lower BackNorway
-
Massachusetts General HospitalOrthopaedic Trauma AssociationCompleted
-
Wayne State UniversityUniversity of MichiganCompleted
-
Wayne State UniversityBlue Cross Blue Shield of Michigan FoundationCompleted
-
Stanford UniversityNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingPain | Joint Pain | Pain, Chronic | Chronic Musculoskeletal PainUnited States
-
Wayne State UniversityUniversity of Southern CaliforniaCompleted
Clinical Trials on Usual Care/Guideline
-
Chinese University of Hong KongThe Queen Elizabeth HospitalUnknown
-
University of AarhusAalborg UniversityCompleted
-
University of Maryland, BaltimoreCompleted
-
University of PittsburghPatient-Centered Outcomes Research Institute; Medical University of South Carolina and other collaboratorsCompletedLow Back PainUnited States
-
Karolinska InstitutetCompleted
-
Vrije Universiteit BrusselCompletedLow Back Pain | Central Sensitisation | Sensory Profiles | Nociplastic PainBelgium
-
University of FloridaBrooks Rehabilitation; Foundation for Physical Therapy ResearchCompletedLow Back Pain | Neck PainUnited States
-
Sanitas UniversityUnknown
-
Medical University of South CarolinaNational Institute of Nursing Research (NINR)CompletedVenous Insufficiency | Venous Ulcers | Venous Disease | Venous Vascular Diseases and SyndromesUnited States
-
Ottawa Hospital Research InstituteActive, not recruiting